Management of non-small cell lung in cancer patients with stable disease

Drugs

Volumn 72, Issue SUPPL. 1, 2012, Pages 20-27

  Grossi, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR;

ADENOSQUAMOUS CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL KILLING; CONFIDENCE INTERVAL; DISEASE COURSE; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; INDUCTION CHEMOTHERAPY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84862577157     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/1163013-S0-000000000-00000     Document Type: Review

References (34)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 Feb 2; 92 (3): 205-16
2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009 Jan; 45 (2): 228-47
3. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981 Jan 1; 47 (1): 207-14 (Pubitemid 11167383)
4. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007 May 1; 25 (13): 1753-9 (Pubitemid 46797957)
5. Sirohi B, Ashley S, Norton A, et al. Early response to platinum- based first-line chemotherapy in non-small cell lung cancer may predict survival. J Thorac Oncol 2007 Aug; 2 (8): 735-40 (Pubitemid 47357528)
6. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after frontline therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009 Feb 1; 27 (4): 591-8
7. Lara Jr PN, Redman MW, Kelly K, et al., Southwest Oncology Group. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008 Jan 20; 26 (3): 463-7 (Pubitemid 351171700)
8. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 2008 Mar-Apr; 28 (2): 329-44
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 Jul 14; 353 (2): 123-32 (Pubitemid 41058344)
10. Azzoli CG, Baker Jr S, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009 Dec 20; 27 (36): 6251-66
11. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 Dec 14; 355 (24): 2542-50 (Pubitemid 44917502)
12. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010 Sep; 21 (9): 1804-9
13. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009Mar 10; 27 (8): 1227-34
14. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009 May 2; 373 (9674): 1525-31
15. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155-63
16. Park JO, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum based chemotherapy in non-small-cell lung cancer. J Clin Oncol 2007; 25: 5233-9
17. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002; 20: 1335-43 (Pubitemid 34182817)
18. von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006; 95: 966-73 (Pubitemid 44606820)
19. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009 Oct 24; 374 (9699): 1432-40
20. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010 Jun; 11 (6): 521-9
21. Soon YY, Stockler MR, Askie LM, et al. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009 Jul 10; 27 (20): 3277-83
22. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. National Comprehensive Cancer Network, 2011. http://www.nccn.org/ [Accessed 2011 Feb 14]
23. D'Addario G, Früh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21 Suppl. 5: v116-19
24. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-33 (Pubitemid 10138923)
25. Day RS. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 1986; 46: 3876-85 (Pubitemid 16075878)
26. Grossi F, Aita M, Follador A, et al. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 2007 Apr; 12 (4): 451-64 (Pubitemid 46698723)
27. Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27 Suppl. 18s: 806s (abstr CRA8000)
28. Available at: http://www.fda.gov/AboutFDA/CentersOffices/ CDER/ ucm170660.htm-accessed. [Accessed 2010 Aug 16]
29. Available at: http://www.ema.europa.eu/docs/en-GB/doc ument-library/EPAR- -WC500090680.pdf. [Accessed 2010 Aug 16]
30. Coudert B, Ciuleanu T, Park K, et al. Survival benefit with erlotinib maintenance therapy relative to prior chemotherapeutic response: a subanalysis of the phase III SATURN study in NSCLC. 2nd European Lung Cancer Conference; 28 April-1 May, 2010; Geneva, Switzerland. Abstract 204O
31. Available at: http://www.fda.gov/AboutFDA/CentersOffices/ CDER/ucm209058.htm-accesed. [Accessed 2010 Aug 16]
32. Available at: http://www.ema.europa.eu/ema/index.jsp?curl- pages/ medicines/human/medicines/000618/smops/Positive/ human-smop- 000085.jsp-accessed. [Accessed 2010 Aug 16]
33. Perol M, Chouaid C, Milleron J, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010; 28 (15s): abstr 7507
34. Paz-Ares LG, De Marinis F, Dediu M, et al. PARAMOUNT: phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29 (18s): abstr CRA7510